SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)

$SMFR
Retail: Computer Software & Peripheral Equipment
Technology
Get the next $SMFR alert in real time by email
SC 13D/A 1 sc13dagenedx12623.htm SC 13D/A Document


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)
GeneDx Holdings, Corp.
(Name of Issuer)
Class A Common Stock, par value $0.0001 per share
(Title of Class of Securities)
81663L101
(CUSIP Number)
Steven D. Rubin
Executive Vice President - Administration
OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, Florida 33137
Telephone: (305) 575-4100
(Name, address and telephone number of person authorized to receive notices and communications)
January 26, 2023
(Date of event which requires filing of this statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box  ¨.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






1
NAME OF REPORTING PERSONS
 
OPKO Health, Inc.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)  ¨        (b)  ¨
 
3
SEC USE ONLY
 
4
SOURCE OF FUNDS
 
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
NUMBER OF   SHARES
BENEFICIALLY OWNED BY
EACH REPORTING
PERSON
WITH
7
SOLE VOTING POWER 
94,285,714 

8
SHARED VOTING POWER
9
SOLE DISPOSITIVE POWER
 

94,285,714 

10
SHARED DISPOSITIVE POWER

11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

  
94,285,714 

12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ¨
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
11.6 %
(1)
14
TYPE OF REPORTING PERSON
CO

(1)    Based on 810,000,334 shares of GeneDx Common Stock (as defined herein) of the Issuer (as defined herein) to be outstanding immediately after the Issuer’s Offering (as defined herein) as set forth in the Issuer’s Prospectus on Form 424 filed with the SEC (as defined herein) on January 30, 2023.







EXPLANATORY NOTE
This Amendment No. 1 (the “Amendment”) to Schedule 13D is being filed with the Securities and Exchange Commission (the “SEC”) on behalf of OPKO Health, Inc., a Delaware corporation (“OPKO”) and relates to the Class A common stock, par value $0.0001 per share (“GeneDx Common Stock”), of GeneDx Holdings Corp., a Delaware corporation (“GeneDx” or the “Issuer”) and amends and supplements the initial statement on Schedule 13D filed by OPKO with the SEC on May 9, 2022 (the “Schedule 13D”). Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Schedule 13D.
ITEM 2.
Identity and Background.
Schedule I is hereby amended as follows:
Jon Cohen has retired from OPKO and is therefore no longer a director and officer and the following directors and officers have been added.
Directors of OPKO
NameBusiness AddressPrincipal Occupation or EmploymentCitizenship
Elias A. Zerhouni, M.D.c/o OPKO Health, Inc.
4400 Biscayne Blvd.
Miami, Florida 33137
Vice Chairman of the Board and President of OPKO Health, Inc.United States
Gary J. Nabel, M.D., Ph.D.c/o OPKO Health, Inc.
4400 Biscayne Blvd.
Miami, Florida 33137
Chief Innovation Officer of OPKO Health Inc.United States
Alexis Borisyc/o OPKO Health, Inc.
4400 Biscayne Blvd.
Miami, Florida 33137
Executive Chairman of the Board of EQRx, Inc.United States

Officers of OPKO
NameBusiness AddressPrincipal Occupation or EmploymentCitizenship
Elias A. Zerhouni, M.D.c/o OPKO Health, Inc.
4400 Biscayne Blvd.
Miami, Florida 33137
President and Vice Chairman of the BoardUnited States
Gary J. Nabel, M.D., Ph.D.c/o OPKO Health, Inc.
4400 Biscayne Blvd.
Miami, Florida 33137
Chief Innovation OfficerUnited States
ITEM 3.
Source and Amount of Funds or Other Consideration.
Item 3 is amended by adding the following paragraph to the end of the item:
On January 26, 2023, OPKO acquired 14,285,714 shares of GeneDx Common Stock in a registered public offering (the “Offering”) at $0.35 per shares for an aggregate purchase price of approximately $5,000,000. The source of funds used to acquire the GeneDx Common Stock was working capital of OPKO.
ITEM 4.
Purpose of Transaction.
Item 4 is amended by adding the following paragraph to the end of the item:
On January 26, 2023, OPKO acquired 14,285,714 shares of GeneDx Common Stock in the Offering at $0.35 per shares for an aggregate purchase price of approximately $5,000,000.




ITEM 5.
Interest in Securities of the Issuer.
Item 5 is deleted in its entirety and replaced with the following text:
(a)    The Company’s beneficial ownership of Sema4 Common Stock is as set forth in the table below:
Name and Title of Beneficial OwnerNumber of Outstanding Shares Beneficially Owned
Percentage of Outstanding Common Shares (1)
OPKO Health, Inc.94,285,71411.6%
______________
(1)    Based on 810,000,334 shares of GeneDx Common Stock outstanding immediately after the Offering, as set forth in the Issuer’s Prospectus on Form 424 filed with the SEC on January 30, 2023.
(b)    Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5.
(c)    The information contained in Item 3 of this Amendment is incorporated by reference in this Item 5. Except as stated herein, OPKO has not effected any transactions in the shares of GeneDx Common Stock within the last 60 days.
(d)    Except as described herein, no other person is known by OPKO to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them.
(e)    Not applicable.







SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

OPKO Health, Inc.
By:
/s/ Steven D. Rubin
Date: February 3, 2023
Name:
Steven D. Rubin
Title:
Executive Vice President-Administration




Get the next $SMFR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SMFR

DatePrice TargetRatingAnalyst
12/7/2022$3.00 → $1.00Buy → Neutral
Goldman
8/16/2022$4.00 → $2.00Buy → Hold
Jefferies
6/2/2022$3.50Buy
Goldman
11/19/2021$12.00Buy
Goldman Sachs
10/8/2021$12.00Buy
BTIG Research
9/30/2021$13.00Outperform
Cowen & Co.
9/24/2021$13.00Buy
Jefferies
More analyst ratings

$SMFR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

    Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology
  • Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

    STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available on the "Events" section of the Sema4|GeneDx investor relations website at https://ir.sema4.com/. About Sema4|GeneDx Sema4|GeneDx is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming

    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology
  • New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

    STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management. The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fai

    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology

$SMFR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SMFR
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$SMFR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SMFR
SEC Filings

See more

$SMFR
Leadership Updates

Live Leadership Updates

See more
  • Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

    STAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO position. Mr. Feeley, who has held the roles of Senior Vice President of Operations and Head of GeneDx at Sema4 since May 2022, will also continue to lead all key operational aspects of the Company. "As we shared during our recent earnings call, our new management team is committed to profitable growth, efficiency, and scale. Kevin's broad industry experience and successful financial leadership of GeneDx during an accelerated phase of commercial

    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology
  • Sema4 Announces Chief Financial Officer Transition Plan

    Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced its Chief Financial Officer (CFO), Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Sema4's Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities. "We are extremely thankful fo

    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology

$SMFR
Financials

Live finance-specific insights

See more
  • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

    Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology
  • Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

    Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity

    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology
  • Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

    STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast

    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology

$SMFR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more